Post-approval studies (Phase 4)Ended earlyNCT03119662
What this trial is testing
Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease
Who this might be right for
Chronic Kidney Diseases
GE Healthcare 4
Showing 5 of 5 results